title: "AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved >90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026"
date: "2025-10-27"
published: true
sources:
  - name: marketwatch
    url: https://www.marketwatch.com/press-release/alphaton-nasdaq-aton-and-cyncado-therapeutics-preclinical-mesothelioma-data-show-direct-a2b-tumor-activity-tt-4-achieved-90-tumor-growth-inhibition-first-patient-dosing-on-track-for-q1-2026-63f45be0?mod=search_headline
summary: ""
